Vertex Pharmaceuticals VRTX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Vertex Pharmaceuticals (VRTX) Core Market Data and Business Metrics
Latest Closing Price
$483.49Price-Earnings Ratio
-232.45Total Outstanding Shares
256.79 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
50 Northern Avenue, Boston, MA, 02210
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,362,654 Shares | 4.22 | 3/14/2025 | 5,753,349 Shares |
| 1,395,128 Shares | 3.93 | 2/28/2025 | 5,484,026 Shares |
| 1,459,354 Shares | 3.47 | 2/14/2025 | 5,066,603 Shares |
| 1,589,768 Shares | 2.87 | 1/31/2025 | 4,561,796 Shares |
| 1,538,051 Shares | 2.86 | 1/15/2025 | 4,394,404 Shares |
| 2,473,678 Shares | 1.6 | 12/31/2024 | 3,955,628 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Exchange Gains/Losses | $-42.60 Million |
| Net Cash Flow From Financing Activities | $-1.49 Billion |
| Net Cash Flow | $-5.80 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-3.77 Billion |
| Net Cash Flow From Operating Activities, Continuing | $-492.60 Million |
| Net Cash Flow From Financing Activities, Continuing | $-1.49 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Operating Expenses | $8.26 Billion |
| Net Income/Loss | $-535.60 Million |
| Gross Profit | $9.49 Billion |
| Income/Loss From Continuing Operations After Tax | $-535.60 Million |
| Cost Of Revenue | $1.53 Billion |
| Operating Expenses | $9.72 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss Attributable To Parent | $142.10 Million |
| Comprehensive Income/Loss | $-393.50 Million |
| Other Comprehensive Income/Loss | $-393.50 Million |
| Comprehensive Income/Loss Attributable To Parent | $-393.50 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Assets | $9.60 Billion |
| Assets | $22.53 Billion |
| Intangible Assets | $825.90 Million |
| Inventory | $1.21 Billion |
| Equity Attributable To Parent | $16.41 Billion |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||